Company news
Hemogenyx Pharmaceuticals Plc (LSE:HEMO) news
Hemogenyx Pharmaceuticals Plc news releases on 6ix. Latest, Dec 30, 2024: Opening of First Clinical Site
Press releases — page 2
Opening of First Clinical Site
December 30, 2024
Ultrafast CAR-T Manufacturing
December 19, 2024
Admission of New Ordinary Shares and New ISIN
December 10, 2024
Result of Extraordinary General Meeting
December 9, 2024
CBR Macrophage Delivery Update
December 6, 2024
Notice of Extraordinary General Meeting
November 22, 2024
Institutional Investment
November 11, 2024
Schedule for Phase I Clinical Trial Opening
October 30, 2024
Strategic Investment from Prevail Partners, LLC
October 2, 2024
Hemogenyx Pharmaceuticals plc - Half-year Report
September 30, 2024
Half-year Report
September 27, 2024
FLT3 Assay Ready for Phase I Trials at MD Anderson
September 9, 2024
CDX Development Update
September 2, 2024
Presentation at CBD S&T Conference
August 28, 2024
Macrophage-Directed Therapies Summit Presentation
July 29, 2024
Result of Annual General Meeting
June 27, 2024
Operations Update
June 17, 2024
Posting of Annual Report & Notice of AGM
June 3, 2024
Final Results
April 25, 2024
Placing to Raise US$4.2 million
February 29, 2024
CBR Brain Delivery
February 16, 2024
CBR Intranasal Delivery
February 14, 2024
FDA Consents to Phase I Trials of HEMO-CAR-T
February 9, 2024
Approval and Issuance of U.S. Conditioning Patent
February 2, 2024
Submission of Complete Response to Clinical Hold
January 16, 2024
HEMO-CAR-T Process Qualification Run Completed
January 8, 2024
Placing to Raise £534,375
November 28, 2023
CBR Expanded to Treatment of Cancer
November 27, 2023
Lentivirus Re-manufacturing Completed
November 15, 2023
Hemogenyx Pharmaceuticals Announces Strategic Investment from Prevail Partners, LLC
September 19, 2023
Clinical Hold Lift Plan is accepted by FDA
September 14, 2023
CBR Patent Application Update
September 8, 2023
Full FDA Review for HEMO-CAR-T IND
July 10, 2023
Clinical Hold on IND for HEMO-CAR-T
June 2, 2023
Submission of IND for HEMO-CAR-T
May 9, 2023
Equity Incentive Pool Increase and Option Grant
April 28, 2023
HEMO-CAR-T Analytical Release Tests Completed
March 23, 2023
Admission of Shares to Official List
February 7, 2023
Second Price Monitoring Extn
January 26, 2023
HEMO-CAR-T 3rd Process Qualification Run Completed
January 23, 2023
Price Monitoring Extension
January 16, 2023
Single CBR Can Treat Multiple Viruses
January 9, 2023
HEMO-CAR-T First PQ Run Completed
December 12, 2022
HEMO-CAR-T Process Development Runs Completed
November 18, 2022
Presentation at H.C. Wainwright Global Conference
September 1, 2022
Appointment of Director of Quality
August 22, 2022
Approval and Issuance of Antibody Patent
August 15, 2022
Appointment of Medical Director
August 10, 2022
New Custom R&D Facility Opening
July 13, 2022
Investor Webinar Recording
July 8, 2022